Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC

SIMPLE SUMMARY: Immunotherapy with immune checkpoint inhibitors has recently brought a paradigm shift in the treatment of non-small cell lung cancer (NSCLC), but until now, most clinical benefits of immunotherapy have been demonstrated in the setting of advanced or metastatic disease. However, there...

Descripción completa

Detalles Bibliográficos
Autores principales: Roller, John F., Veeramachaneni, Nirmal K., Zhang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833612/
https://www.ncbi.nlm.nih.gov/pubmed/35159008
http://dx.doi.org/10.3390/cancers14030741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833612/
https://www.ncbi.nlm.nih.gov/pubmed/35159008
http://dx.doi.org/10.3390/cancers14030741

Ejemplares similares